The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

As the World Health Organization initiates a new agreement for coordinating global responses to future pandemics, the future ...

Novavax, Inc. (“Novavax”) announced that FDA approved its Biologics License Application (“BLA”) for Nuvaxovid™ for active ...

In a video posted to social media on Tuesday, HHS Secretary Robert F. Kennedy, Jr. claimed that there is a lack of clinical ...

Novavax, Inc. (Nasdaq: NVAX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Nuvaxovid™ for active immunization to ...

The FDA expects that randomized, controlled trial data on clinical outcomes will be needed before COVID-19 vaccines can be approved for patients who are 6 months to 64 years of age and do not have ...

Nuvaxovid, a two-shot treatment to prevent ... The protein is combined with Novavax's Matrix-M adjuvant, which is important in enhancing the immune response elicited by the protein antigen.

On May 20, BofA analyst Alec Stranahan reiterated a Hold rating on Novavax, Inc. (NASDAQ:NVAX) stock, setting a price target of $10. The approval of Nuvaxovid for use in older and high-risk adults ...

The company has started to add bearish views on Wall Street as the healthcare giant's business practices draw public scrutiny, risking its prospects, worsened by its recent leadership change. Bank of ...

Moderna MRNA announced that it has submitted a regulatory filing with the FDA seeking approval for an updated version of its ...